the aid library

Key
Resources
Clinical
Guidelines
Women & Child
Health
Pharmacy &
Technologies
Public
Health
Capacity
Building
COUNTRIES
TOOLBOXES
- Conflict
- Zika
- TB
- Cholera
- HIV
- Polio
- Rapid Response
- Refugee
- Disability
- Specific Hazards
- Social Ethics
- Health Financing Toolbox

Middle East and North Africa
West and Central Africa
East and Southern Africa
South–East Asia Region
Western Pacific Region
Eastern Europe and Central Asia
Latin America and the Carribbean
Western and Central Europe
North America
South Sudan
Turkmenistan
Jamaica
Japan
Belgium
France
Maldives
Mauritius
Tunisia
Portugal
Spain
South Korea
Algeria
Azerbaijan
Belarus
French Guyana
Israel

Login
Register
English

Search database

Suggest new resources

Filter

29

Text search: colchicine

Featured

Recommendations

8

New Publications

6

Language

English

26

Spanish

1

German

1

French

1

Document type

Guidelines

16

No document type

7

Studies & Reports

3

Manuals

2

Fact sheets

1

Countries / Regions

India

3

Philippines

2

Germany

2

South Africa

2

Burkina Faso

1

Ethiopia

1

Nepal

1

Kenya

1

Rwanda

1

Namibia

1

Brazil

1

Botswana

1

Latin America and the Carribbean

1

Paraguay

1

Solomon Islands

1

Global

1

Authors & Publishers

World Health Organization WHO

4

National Department of Health, South Africa

2

Pan American Health Organisation PAHO

2

Robert-Koch-Institut RKI

2

Aday A.W.

1

Anna Melissa S. Guerrero

1

Botswana Essential Drug Action Programme (BEDAP), Ministry of Health, Republic of Botswana

1

Circulation Research

1

Department of Health (DOH)

1

E. André

1

et al.

1

Food, Medicine and Healthcare Administration and Control Authority of Ethiopia

1

Frontiers in Pediatrics

1

Hepatology Society of the Philippines (HSP)

1

Lawrence Flick Memorial Tuberculosis Clinic, Philadelphia Tuberculosis Control Program

1

Mark F. Cotton

1

Matsushita, K.

1

Ministere de la Sante, Burkina Faso

1

Ministry of Health & Family Welfare (MOHFW), Government of India

1

Ministry of Health & Family Welfare, India

1

Ministry of Health and Social Services (MOHSS)

1

Ministry of Health and Social Welfare, India

1

Ministry of Health Kenya

1

National Pharmacy Services Division, Ministry of Health & Medical Services

1

NDoH South Africa

1

Republic of Kenya

1

Republic of Rwanda, Ministry of Health

1

S. H.-L. Fry

1

S. L. Barnabas

1

Sandy Greenwood, Timmy Manea, Willie Horoto et al.

1

SickKids

1

Sociedad Paraguaya de Infectologia (SPI)

1

SPI

1

Stephen N. Wong, Jane R. Campos, Ian Homer Y. Cua et al.

1

World Health Organisation (WHO)

1

Zaidel, E.J.

1

Publication Years

2020-2026

16

2010-2019

10

2000-2009

2

1990-1999

1

Category

Countries

19

Public Health

1

Clinical Guidelines

1

Key Resources

1

Toolboxes

COVID-19

12

Pharmacy

6

NCDs

2

HIV

1

TB

1

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi ... th severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19. more

Myocarditis and pericarditis after mRNA COVID-19 vaccination in children: Interim guidance

SickKids (2020) CC

COVID-19 Guidelines Module 5 - Drug therapy

National Department of Health, South Africa NDoH South Africa (2021) CC

Botswana Essential Drug List (BEDL)

Botswana Essential Drug Action Programme (BEDAP), Ministry of Health, Republic of Botswana (2012) C2

Second Edition, 2012

Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. Rapid Review

Pan American Health Organisation PAHO (2020) C_WHO

As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I ... n this review, 46 therapeutic options are examined. The Pan American Health Organization (PAHO) is continually monitoring ongoing research on any possible therapeutic options. As evidence emerges, then PAHO will immediately assess and update its position, and particularly as it applies to any special sub-group populations such as children, expectant mothers, those with immune conditions, etc. more

Safety and monitoring for patients receiving Nirmatrelvir-ritonavir for COVID-19
recommended

World Health Organization WHO (2022) C_WHO

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHO Model Formulary
recommended

World Health Organization WHO (2008) C_WHO

For each medicine the Formulary provides information on use, dosage, adverse effects, contraindications and warnings, supplemented by guidance on selecting the right medicine for a range of conditions

List of Medicines for Ethiopia

Food, Medicine and Healthcare Administration and Control Authority of Ethiopia (2010) C1

6th edition

National Formulary of India

Ministry of Health and Social Welfare, India (2011) C1

Solomon Islands Essential Medical Supplies List 2017

Sandy Greenwood, Timmy Manea, Willie Horoto et al. National Pharmacy Services Division, Ministry of Health & Medical Services (2017) CC

Solomon Islands pharmacy staff have developed an essential medicines supplies list. It was a collaborative effort involving a lot of staff taking the pictures and putting it all together. The list was launched as an initiative to improve the availability of medical stock within the country

The 2014 Hepatology Society of the Philippines Consensus Statements on the Diagnosis and Treatment of Hepatitis C

Stephen N. Wong, Jane R. Campos, Ian Homer Y. Cua et al. Hepatology Society of the Philippines (HSP) (2006) C1

Philippines: Drug Price Reference List
recommended

Anna Melissa S. Guerrero Department of Health (DOH) (2015) C1

Nepal: National List of Essential Medicines, 2021
recommended

World Health Organisation (WHO) (2021) C_WHO

6th edition, The NLEM 2021 contains 398 drugs molecules in different therapeutic categories.

India: National List of Essential Medicines 2015

Ministry of Health & Family Welfare (MOHFW), Government of India (2015) C_WHO

National List of Essential Medicines for Adults Rwanda 6th edition

Republic of Rwanda, Ministry of Health (2015) C1

The essential medicines are those that meet the priority needs of the healthcare of the population. While reviewing the 5th edition of the essential Medicines, special attention focused on the health sector policy. Indeed, medicines play an important role in protecting, maintaining and restoring th ... e peoples’ health and credibility of health facilities. Their availability is a fundamental aspect of primary health care as defined in different declarations including Alma-Ata of 1978. more

NEMLIST: Namibia Essential Medicines List

Ministry of Health and Social Services (MOHSS) (2016) C2

NEMLIST | Sixth Edition | February 2016

Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents

Lawrence Flick Memorial Tuberculosis Clinic, Philadelphia Tuberculosis Control Program (1998) C2

Liste Nationale des Médicaments et Consommables Medicaux Essentiels Burkina Faso

Ministere de la Sante, Burkina Faso (2020) C_WHO

Liste nationale

Tuberculosis and HIV—An Update on the “Cursed Duet” in Children

S. H.-L. Fry; S. L. Barnabas; Mark F. Cotton; E. André Frontiers in Pediatrics (2019) C2

Frontiers in Pediatrics | www.frontiersin.org 1 April 2019 | Volume 7 | Article 159

1
2
›
»

Create your own
Login

Home
Contact
Data privacy
Legal notice
FAQ
About
Sitemap

A Project by

medbox @ 2026